Childhood Acute Lymphoblastic Leukemia, Chronic Constipation With Overflow, Constipation, Neurofibromatosis 1
Conditions
Brief summary
To gain a better understanding of the underlying dysmotility in constipation in children, we will use a novel minimal invasive method called 3D Transit. We will examine four groups of children aged 7 to 17 years: healthy children, chronically constipated children (ROM IV criteria), children with neurofibromatosis type 1 and finally children receiving chemotherapy (vincristin) for acute lymphoblastic leukemia.
Interventions
DIAGNOSTIC_TEST3D-Transit
3D transit investigation consists of a small electromagnetic pill and a detector located in a belt around the waist. The pill is swallowed by the participant and the belt is worn until the pill has left the gastrointestinal tract. The method is without any pain and discomfort for the child. The child will visit the hospital the first time to ingest the capsule alongside a standardized meal, and is then free to go home and proceed with daily activities (beside hard exersize) while wearing the belt with the detector. The next day, the child will again visit the hospital to check whether or not the capsule has left the tract - this is done with a computer and software. The children ingesting two capsules will do this with a certain delay.
Sponsors
University of Aarhus
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
7 Years to 17 Years
Healthy volunteers
Yes
Inclusion criteria
applicable to all participants: • Children between 7-17 years of age where permission is granted for the participation by habitable parents with custody of the child. In case of joint custody, permission must be obtained from both parents. Inclusion criteria applicable only to healthy participants: • Gastrointestinal healthy children without chronic constipation Inclusion criteria applicable only to constipated participants: • Chronic constipation defined by Rom IV criteria, which is a diagnostic score for chronic constipation Inclusion criteria applicable only to children in vincristine treatment: • Children with cancer in treatment with vincristine Inclusion criteria applicable only to patients with NF1: • Diagnosis of NF1 with gastrointestinal symptoms
Exclusion criteria
* Children with parents who are unable to understand the given particpant's information * Children with known dysregulated metabolic disease * Previously major intra-abdominal surgery * CNS surgery * Other treatment-requiring gastrointestinal disorder * Systemic steroid treatment within the last week * Children with difficulty swallowing * Children with known gastrointestinal obstruction or perforation * Acute infections * Diagnosed malabsorption including bile acid malabsorption * Menarche in girls
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The investigation is without discomfort and adverse events. | 3 days |
| Children with chronic constipation has a longer transit time through the colon and fewer fast bowel movements than healthy children. | 3 days |
| Children in Vincristine treatment has a longer transit time through the colon and fewer fast bowel movements than healthy children. | 3 days |
| Children with NF1 and gastrointestinal symptoms has a longer transit time through the colon and fewer fast bowel movements than healthy children. | 3 days |
Countries
Denmark
Contacts
Primary ContactKlaus Krogh, Professor, PhD, MD
Outcome results
None listed